TY  - JOUR
AU  - Stanojević, Boban
AU  - Saenko, Vladimir
AU  - Todorović, Lidija
AU  - Petrović, Nina
AU  - Nikolić, Dragan
AU  - Živaljević, Vladan R.
AU  - Paunović, Ivan R.
AU  - Nakashima, Masahiro
AU  - Yamashita, Shunichi
AU  - Džodić, Radan R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/340
AB  - Alterations of the von Hippel-Lindau (VHL) tumor suppressor gene can cause different hereditary tumors associated with VHL syndrome, but the potential role of the VHL gene in papillary thyroid carcinoma (PTC) has not been characterized. This study set out to investigate the relationship of VHL expression level with clinicopathological features of PTC in an ethnically and geographically homogenous group of 264 patients from Serbia, for the first time. Multivariate logistic regression analysis showed a strong correlation between low level of VHL expression and advanced clinical stage (OR=5.78, 95% CI 3.17-10.53, P LT 0.0001), classical papillary morphology of the tumor (OR=2.92, 95% CI 1.33-6.44, P=0.008) and multifocality (OR=1.96, 95% CI 1.06-3.62, P=0.031). In disease-free survival analysis, low VHL expression had marginal significance (P=0.0502 by the log-rank test) but did not appear to be an independent predictor of the risk for chance of faster recurrence in a proportion hazards model. No somatic mutations or evidence of VHL downregulation via promoter hypermethylation in PTC were found. The results indicate that the decrease of VHL expression associates with tumor progression but the mechanism of downregulation remains to be elucidated.
T2  - PLOS One
T1  - Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma
VL  - 9
IS  - 12
DO  - 10.1371/journal.pone.0114511
ER  - 

@article{
author = "Stanojević, Boban and Saenko, Vladimir and Todorović, Lidija and Petrović, Nina and Nikolić, Dragan and Živaljević, Vladan R. and Paunović, Ivan R. and Nakashima, Masahiro and Yamashita, Shunichi and Džodić, Radan R.",
year = "2014",
abstract = "Alterations of the von Hippel-Lindau (VHL) tumor suppressor gene can cause different hereditary tumors associated with VHL syndrome, but the potential role of the VHL gene in papillary thyroid carcinoma (PTC) has not been characterized. This study set out to investigate the relationship of VHL expression level with clinicopathological features of PTC in an ethnically and geographically homogenous group of 264 patients from Serbia, for the first time. Multivariate logistic regression analysis showed a strong correlation between low level of VHL expression and advanced clinical stage (OR=5.78, 95% CI 3.17-10.53, P LT 0.0001), classical papillary morphology of the tumor (OR=2.92, 95% CI 1.33-6.44, P=0.008) and multifocality (OR=1.96, 95% CI 1.06-3.62, P=0.031). In disease-free survival analysis, low VHL expression had marginal significance (P=0.0502 by the log-rank test) but did not appear to be an independent predictor of the risk for chance of faster recurrence in a proportion hazards model. No somatic mutations or evidence of VHL downregulation via promoter hypermethylation in PTC were found. The results indicate that the decrease of VHL expression associates with tumor progression but the mechanism of downregulation remains to be elucidated.",
journal = "PLOS One",
title = "Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma",
volume = "9",
number = "12",
doi = "10.1371/journal.pone.0114511"
}

Stanojević, B., Saenko, V., Todorović, L., Petrović, N., Nikolić, D., Živaljević, V. R., Paunović, I. R., Nakashima, M., Yamashita, S.,& Džodić, R. R.. (2014). Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma. in PLOS One, 9(12).
https://doi.org/10.1371/journal.pone.0114511

Stanojević B, Saenko V, Todorović L, Petrović N, Nikolić D, Živaljević VR, Paunović IR, Nakashima M, Yamashita S, Džodić RR. Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma. in PLOS One. 2014;9(12).
doi:10.1371/journal.pone.0114511 .

Stanojević, Boban, Saenko, Vladimir, Todorović, Lidija, Petrović, Nina, Nikolić, Dragan, Živaljević, Vladan R., Paunović, Ivan R., Nakashima, Masahiro, Yamashita, Shunichi, Džodić, Radan R., "Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma" in PLOS One, 9, no. 12 (2014),
https://doi.org/10.1371/journal.pone.0114511 . .

TY  - JOUR
AU  - Markićević, Milan
AU  - Džodić, Radan R.
AU  - Buta, Marko
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/203
AB  - Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - International Journal of Medical Sciences
T1  - Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up
VL  - 11
IS  - 7
SP  - 663
EP  - 673
DO  - 10.7150/ijms.8194
ER  - 

@article{
author = "Markićević, Milan and Džodić, Radan R. and Buta, Marko and Kanjer, Ksenija and Mandušić, Vesna and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2014",
abstract = "Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "International Journal of Medical Sciences",
title = "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up",
volume = "11",
number = "7",
pages = "663-673",
doi = "10.7150/ijms.8194"
}

Markićević, M., Džodić, R. R., Buta, M., Kanjer, K., Mandušić, V., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2014). Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences, 11(7), 663-673.
https://doi.org/10.7150/ijms.8194

Markićević M, Džodić RR, Buta M, Kanjer K, Mandušić V, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences. 2014;11(7):663-673.
doi:10.7150/ijms.8194 .

Markićević, Milan, Džodić, Radan R., Buta, Marko, Kanjer, Ksenija, Mandušić, Vesna, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up" in International Journal of Medical Sciences, 11, no. 7 (2014):663-673,
https://doi.org/10.7150/ijms.8194 . .

TY  - JOUR
AU  - Tanić, Nasta
AU  - Milinković, Vedrana
AU  - Dramićanin, Tatjana
AU  - Nedeljković, Milica
AU  - Stanković, Tijana
AU  - Milovanović, Zorka M.
AU  - Šušnjar, Snežana
AU  - Milošević, Verica
AU  - Šošić-Jurjević, Branka
AU  - Džodić, Radan R.
AU  - Tanić, Nikola
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5745
AB  - Background: Breast cancer is the most common form of cancer in women. It arises from multiple genetic changes in oncogenes and tumor suppressor genes. Among so far studied oncogenes relatively few, including epdermal growth factor receptor (EGFR), cyclinD1 (CCND1) and c-myc, have been found to play an important role in progression of this type of human malignancy. The aim of this study was to examine the prognostic potential of CCND1, c-myc and EGFR amplification and their possible cooperation in breast carcinogenesis. Methods: Copy number analyses of CCND1 and c-myc genes were done by TaqMan based quantitative real time PCR. Amplification status of EGFR was determined by differential PCR. Results: Amplification of CCND1, c-myc and EGFR oncogene has been found in 20.4%, 26.5% and 26.5% of breast cancer cases, respectively. Analysis showed that amplification of CCND1 oncogene was significantly associated with the stage II of disease while amplification of EGFR gene was significantly associated with overexpression of HER-2/neu. Tumour stage and expression of HER-2/neu appeared to be significant predictors of patients outcome. Stage I patients lived significantly longer then stage III patients (p=0.04) while patients with HER-2/neu overexpression had worse prognoses and lived significantly shorter (p=0.001). Finally, survival of patients who underwent hormone therapy only was significantly longer (p=0.001) then survival of the rest of patients. Conclusions: Amplification of CCND1 or EGFR oncogene is associated with the progression of breast cancer and bad prognosis. No co-ordination in amplification of CCND1, c-myc and EGFR oncogenes were established in this cohort of breast cancer patients.
T2  - Journal of Medical Biochemistry
T1  - Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients
VL  - 32
IS  - 4
DO  - 10.2478/jomb-2014-0005
ER  - 

@article{
author = "Tanić, Nasta and Milinković, Vedrana and Dramićanin, Tatjana and Nedeljković, Milica and Stanković, Tijana and Milovanović, Zorka M. and Šušnjar, Snežana and Milošević, Verica and Šošić-Jurjević, Branka and Džodić, Radan R. and Tanić, Nikola",
year = "2013",
abstract = "Background: Breast cancer is the most common form of cancer in women. It arises from multiple genetic changes in oncogenes and tumor suppressor genes. Among so far studied oncogenes relatively few, including epdermal growth factor receptor (EGFR), cyclinD1 (CCND1) and c-myc, have been found to play an important role in progression of this type of human malignancy. The aim of this study was to examine the prognostic potential of CCND1, c-myc and EGFR amplification and their possible cooperation in breast carcinogenesis. Methods: Copy number analyses of CCND1 and c-myc genes were done by TaqMan based quantitative real time PCR. Amplification status of EGFR was determined by differential PCR. Results: Amplification of CCND1, c-myc and EGFR oncogene has been found in 20.4%, 26.5% and 26.5% of breast cancer cases, respectively. Analysis showed that amplification of CCND1 oncogene was significantly associated with the stage II of disease while amplification of EGFR gene was significantly associated with overexpression of HER-2/neu. Tumour stage and expression of HER-2/neu appeared to be significant predictors of patients outcome. Stage I patients lived significantly longer then stage III patients (p=0.04) while patients with HER-2/neu overexpression had worse prognoses and lived significantly shorter (p=0.001). Finally, survival of patients who underwent hormone therapy only was significantly longer (p=0.001) then survival of the rest of patients. Conclusions: Amplification of CCND1 or EGFR oncogene is associated with the progression of breast cancer and bad prognosis. No co-ordination in amplification of CCND1, c-myc and EGFR oncogenes were established in this cohort of breast cancer patients.",
journal = "Journal of Medical Biochemistry",
title = "Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients",
volume = "32",
number = "4",
doi = "10.2478/jomb-2014-0005"
}

Tanić, N., Milinković, V., Dramićanin, T., Nedeljković, M., Stanković, T., Milovanović, Z. M., Šušnjar, S., Milošević, V., Šošić-Jurjević, B., Džodić, R. R.,& Tanić, N.. (2013). Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients. in Journal of Medical Biochemistry, 32(4).
https://doi.org/10.2478/jomb-2014-0005

Tanić N, Milinković V, Dramićanin T, Nedeljković M, Stanković T, Milovanović ZM, Šušnjar S, Milošević V, Šošić-Jurjević B, Džodić RR, Tanić N. Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients. in Journal of Medical Biochemistry. 2013;32(4).
doi:10.2478/jomb-2014-0005 .

Tanić, Nasta, Milinković, Vedrana, Dramićanin, Tatjana, Nedeljković, Milica, Stanković, Tijana, Milovanović, Zorka M., Šušnjar, Snežana, Milošević, Verica, Šošić-Jurjević, Branka, Džodić, Radan R., Tanić, Nikola, "Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients" in Journal of Medical Biochemistry, 32, no. 4 (2013),
https://doi.org/10.2478/jomb-2014-0005 . .

TY  - JOUR
AU  - Stanojević, Boban
AU  - Džodić, Radan R.
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Krstevski, Vesna
AU  - Radlovic, Petar
AU  - Buta, Marko
AU  - Rulic, Bozidar
AU  - Todorović, Lidija
AU  - Dimitrijević, Bogomir B.
AU  - Yamashita, Shunichi
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4970
AB  - Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its prognosis corresponds to that of malignant tumors originating in the thyroid. Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal thyroid tissue ( GT 50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC). Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT - GT GTT transversion, corresponding to the Gly - GT Val amino acid change was identified in the absence of other genetic alterations commonly found in PTC. Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic methods of thyroid malignancy in SO.
T2  - BMC Cancer
T1  - Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report
VL  - 12
DO  - 10.1186/1471-2407-12-224
ER  - 

@article{
author = "Stanojević, Boban and Džodić, Radan R. and Saenko, Vladimir and Milovanović, Zorka M. and Krstevski, Vesna and Radlovic, Petar and Buta, Marko and Rulic, Bozidar and Todorović, Lidija and Dimitrijević, Bogomir B. and Yamashita, Shunichi",
year = "2012",
abstract = "Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its prognosis corresponds to that of malignant tumors originating in the thyroid. Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal thyroid tissue ( GT 50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC). Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT - GT GTT transversion, corresponding to the Gly - GT Val amino acid change was identified in the absence of other genetic alterations commonly found in PTC. Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic methods of thyroid malignancy in SO.",
journal = "BMC Cancer",
title = "Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report",
volume = "12",
doi = "10.1186/1471-2407-12-224"
}

Stanojević, B., Džodić, R. R., Saenko, V., Milovanović, Z. M., Krstevski, V., Radlovic, P., Buta, M., Rulic, B., Todorović, L., Dimitrijević, B. B.,& Yamashita, S.. (2012). Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. in BMC Cancer, 12.
https://doi.org/10.1186/1471-2407-12-224

Stanojević B, Džodić RR, Saenko V, Milovanović ZM, Krstevski V, Radlovic P, Buta M, Rulic B, Todorović L, Dimitrijević BB, Yamashita S. Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. in BMC Cancer. 2012;12.
doi:10.1186/1471-2407-12-224 .

Stanojević, Boban, Džodić, Radan R., Saenko, Vladimir, Milovanović, Zorka M., Krstevski, Vesna, Radlovic, Petar, Buta, Marko, Rulic, Bozidar, Todorović, Lidija, Dimitrijević, Bogomir B., Yamashita, Shunichi, "Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report" in BMC Cancer, 12 (2012),
https://doi.org/10.1186/1471-2407-12-224 . .

TY  - JOUR
AU  - Tanić, Nikola
AU  - Milovanović, Zorka M.
AU  - Tanić, Nasta
AU  - Džodić, Radan R.
AU  - Juranic, Zorica
AU  - Šušnjar, Snežana
AU  - Plesinac-Karapandzic, Vesna
AU  - Tatic, Svetislav
AU  - Dramićanin, Tatjana
AU  - Davidović, Radoslav S.
AU  - Dimitrijević, Bogomir B.
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5073
AB  - Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.
T2  - Cancer Biology and Therapy
T1  - The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients
VL  - 13
IS  - 12
SP  - 1165
EP  - 1174
DO  - 10.4161/cbt.21346
ER  - 

@article{
author = "Tanić, Nikola and Milovanović, Zorka M. and Tanić, Nasta and Džodić, Radan R. and Juranic, Zorica and Šušnjar, Snežana and Plesinac-Karapandzic, Vesna and Tatic, Svetislav and Dramićanin, Tatjana and Davidović, Radoslav S. and Dimitrijević, Bogomir B.",
year = "2012",
abstract = "Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.",
journal = "Cancer Biology and Therapy",
title = "The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients",
volume = "13",
number = "12",
pages = "1165-1174",
doi = "10.4161/cbt.21346"
}

Tanić, N., Milovanović, Z. M., Tanić, N., Džodić, R. R., Juranic, Z., Šušnjar, S., Plesinac-Karapandzic, V., Tatic, S., Dramićanin, T., Davidović, R. S.,& Dimitrijević, B. B.. (2012). The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. in Cancer Biology and Therapy, 13(12), 1165-1174.
https://doi.org/10.4161/cbt.21346

Tanić N, Milovanović ZM, Tanić N, Džodić RR, Juranic Z, Šušnjar S, Plesinac-Karapandzic V, Tatic S, Dramićanin T, Davidović RS, Dimitrijević BB. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. in Cancer Biology and Therapy. 2012;13(12):1165-1174.
doi:10.4161/cbt.21346 .

Tanić, Nikola, Milovanović, Zorka M., Tanić, Nasta, Džodić, Radan R., Juranic, Zorica, Šušnjar, Snežana, Plesinac-Karapandzic, Vesna, Tatic, Svetislav, Dramićanin, Tatjana, Davidović, Radoslav S., Dimitrijević, Bogomir B., "The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients" in Cancer Biology and Therapy, 13, no. 12 (2012):1165-1174,
https://doi.org/10.4161/cbt.21346 . .

TY  - JOUR
AU  - Džodić, Radan R.
AU  - Marković, Ivan
AU  - Stanojević, Boban
AU  - Saenko, Vladimir
AU  - Buta, Marko
AU  - Đurišić, Igor
AU  - Oruci, Merima
AU  - Pupić, Gordana
AU  - Milovanović, Zorka M.
AU  - Yamashita, Shunichi
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4922
AB  - Thyroglossal duct cyst (TDC) carcinoma is a comparable rare entity and treatment strategies have not been standardized. Here, we report a favorable outcome of TDC carcinoma patients based on our therapeutic strategy. Twelve patients with TDC carcinoma treated in our department from 1986 to 2012 were enrolled. Ten patients underwent Sistrunks procedure in other institutions and referred to our institution for re-operation after the diagnosis of TDC carcinoma and the remaining two underwent initial surgery in our institution. Eleven patients were diagnosed as papillary and one as follicular carcinoma originating from TDC. We performed total thyroidectomy for 11, and limited thyroidectomy for one patient. Three patients (25%) had carcinoma lesions in the thyroid. We routinely dissected level I bilaterally and 6 of 11 patients (55%) with papillary carcinoma-type TDC carcinoma had metastasis. Level II/III nodes were biopsied and if positive, we performed level II-IV dissection. Of the 5 patients positive for level II/III, 2 were also positive for level IV. For the 3 patients with synchronous carcinoma in the thyroid, we performed level VI dissection and two had metastasis in this level. To date, 1 patient showed a recurrence to the lung, but none of the patients in our series died of carcinoma. For surgery of TDC carcinoma, Sistrunks procedure, total thyroidectomy with level I dissection is mandatory. Whether level II-IV dissection is performed depends on pathology of biopsied level II/III nodes. Level VI dissection is also recommended especially when carcinoma lesions are pre/intra operatively detected in the thyroid.
T2  - Endocrine Journal
T1  - Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia
VL  - 59
IS  - 6
SP  - 517
EP  - 522
DO  - 10.1507/endocrj.EJ12-0070
ER  - 

@article{
author = "Džodić, Radan R. and Marković, Ivan and Stanojević, Boban and Saenko, Vladimir and Buta, Marko and Đurišić, Igor and Oruci, Merima and Pupić, Gordana and Milovanović, Zorka M. and Yamashita, Shunichi",
year = "2012",
abstract = "Thyroglossal duct cyst (TDC) carcinoma is a comparable rare entity and treatment strategies have not been standardized. Here, we report a favorable outcome of TDC carcinoma patients based on our therapeutic strategy. Twelve patients with TDC carcinoma treated in our department from 1986 to 2012 were enrolled. Ten patients underwent Sistrunks procedure in other institutions and referred to our institution for re-operation after the diagnosis of TDC carcinoma and the remaining two underwent initial surgery in our institution. Eleven patients were diagnosed as papillary and one as follicular carcinoma originating from TDC. We performed total thyroidectomy for 11, and limited thyroidectomy for one patient. Three patients (25%) had carcinoma lesions in the thyroid. We routinely dissected level I bilaterally and 6 of 11 patients (55%) with papillary carcinoma-type TDC carcinoma had metastasis. Level II/III nodes were biopsied and if positive, we performed level II-IV dissection. Of the 5 patients positive for level II/III, 2 were also positive for level IV. For the 3 patients with synchronous carcinoma in the thyroid, we performed level VI dissection and two had metastasis in this level. To date, 1 patient showed a recurrence to the lung, but none of the patients in our series died of carcinoma. For surgery of TDC carcinoma, Sistrunks procedure, total thyroidectomy with level I dissection is mandatory. Whether level II-IV dissection is performed depends on pathology of biopsied level II/III nodes. Level VI dissection is also recommended especially when carcinoma lesions are pre/intra operatively detected in the thyroid.",
journal = "Endocrine Journal",
title = "Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia",
volume = "59",
number = "6",
pages = "517-522",
doi = "10.1507/endocrj.EJ12-0070"
}

Džodić, R. R., Marković, I., Stanojević, B., Saenko, V., Buta, M., Đurišić, I., Oruci, M., Pupić, G., Milovanović, Z. M.,& Yamashita, S.. (2012). Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia. in Endocrine Journal, 59(6), 517-522.
https://doi.org/10.1507/endocrj.EJ12-0070

Džodić RR, Marković I, Stanojević B, Saenko V, Buta M, Đurišić I, Oruci M, Pupić G, Milovanović ZM, Yamashita S. Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia. in Endocrine Journal. 2012;59(6):517-522.
doi:10.1507/endocrj.EJ12-0070 .

Džodić, Radan R., Marković, Ivan, Stanojević, Boban, Saenko, Vladimir, Buta, Marko, Đurišić, Igor, Oruci, Merima, Pupić, Gordana, Milovanović, Zorka M., Yamashita, Shunichi, "Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia" in Endocrine Journal, 59, no. 6 (2012):517-522,
https://doi.org/10.1507/endocrj.EJ12-0070 . .

TY  - JOUR
AU  - Stanojević, Boban
AU  - Džodić, Radan R.
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Pupić, Gordana
AU  - Živković, Ognjen
AU  - Marković, Ivan
AU  - Đurišić, Igor
AU  - Buta, Marko
AU  - Dimitrijević, Bogomir B.
AU  - Rogounovitch, Tatiana
AU  - Mitsutake, Norisato
AU  - Mine, Mariko
AU  - Shibata, Yoshisada
AU  - Nakashima, Masahiro
AU  - Yamashita, Shunichi
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4401
AB  - Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.
T2  - Endocrine Journal
T1  - Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia
VL  - 58
IS  - 5
SP  - 381
EP  - 393
DO  - 10.1507/endocrj.K11E-054
ER  - 

@article{
author = "Stanojević, Boban and Džodić, Radan R. and Saenko, Vladimir and Milovanović, Zorka M. and Pupić, Gordana and Živković, Ognjen and Marković, Ivan and Đurišić, Igor and Buta, Marko and Dimitrijević, Bogomir B. and Rogounovitch, Tatiana and Mitsutake, Norisato and Mine, Mariko and Shibata, Yoshisada and Nakashima, Masahiro and Yamashita, Shunichi",
year = "2011",
abstract = "Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.",
journal = "Endocrine Journal",
title = "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia",
volume = "58",
number = "5",
pages = "381-393",
doi = "10.1507/endocrj.K11E-054"
}

Stanojević, B., Džodić, R. R., Saenko, V., Milovanović, Z. M., Pupić, G., Živković, O., Marković, I., Đurišić, I., Buta, M., Dimitrijević, B. B., Rogounovitch, T., Mitsutake, N., Mine, M., Shibata, Y., Nakashima, M.,& Yamashita, S.. (2011). Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal, 58(5), 381-393.
https://doi.org/10.1507/endocrj.K11E-054

Stanojević B, Džodić RR, Saenko V, Milovanović ZM, Pupić G, Živković O, Marković I, Đurišić I, Buta M, Dimitrijević BB, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal. 2011;58(5):381-393.
doi:10.1507/endocrj.K11E-054 .

Stanojević, Boban, Džodić, Radan R., Saenko, Vladimir, Milovanović, Zorka M., Pupić, Gordana, Živković, Ognjen, Marković, Ivan, Đurišić, Igor, Buta, Marko, Dimitrijević, Bogomir B., Rogounovitch, Tatiana, Mitsutake, Norisato, Mine, Mariko, Shibata, Yoshisada, Nakashima, Masahiro, Yamashita, Shunichi, "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia" in Endocrine Journal, 58, no. 5 (2011):381-393,
https://doi.org/10.1507/endocrj.K11E-054 . .

TY  - CONF
AU  - Džodić, Radan R.
AU  - Marković, Ivan Z.
AU  - Đurišić, Igor
AU  - Buta, Marko
AU  - Pupić, Gordana
AU  - Milovanović, Zorka M.
AU  - Stanojević, Boban
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4037
C3  - Endocrine Journal
T1  - Surgical treatment of papillary thyroid carcinoma in children and adolescents
VL  - 57
SP  - S450
EP  - S450
UR  - https://hdl.handle.net/21.15107/rcub_vinar_4037
ER  - 

@conference{
author = "Džodić, Radan R. and Marković, Ivan Z. and Đurišić, Igor and Buta, Marko and Pupić, Gordana and Milovanović, Zorka M. and Stanojević, Boban",
year = "2010",
journal = "Endocrine Journal",
title = "Surgical treatment of papillary thyroid carcinoma in children and adolescents",
volume = "57",
pages = "S450-S450",
url = "https://hdl.handle.net/21.15107/rcub_vinar_4037"
}

Džodić, R. R., Marković, I. Z., Đurišić, I., Buta, M., Pupić, G., Milovanović, Z. M.,& Stanojević, B.. (2010). Surgical treatment of papillary thyroid carcinoma in children and adolescents. in Endocrine Journal, 57, S450-S450.
https://hdl.handle.net/21.15107/rcub_vinar_4037

Džodić RR, Marković IZ, Đurišić I, Buta M, Pupić G, Milovanović ZM, Stanojević B. Surgical treatment of papillary thyroid carcinoma in children and adolescents. in Endocrine Journal. 2010;57:S450-S450.
https://hdl.handle.net/21.15107/rcub_vinar_4037 .

Džodić, Radan R., Marković, Ivan Z., Đurišić, Igor, Buta, Marko, Pupić, Gordana, Milovanović, Zorka M., Stanojević, Boban, "Surgical treatment of papillary thyroid carcinoma in children and adolescents" in Endocrine Journal, 57 (2010):S450-S450,
https://hdl.handle.net/21.15107/rcub_vinar_4037 .

TY  - JOUR
AU  - Veljkovic, E
AU  - Dzodic, R
AU  - Neskovic, G
AU  - Stanojević, Boban
AU  - Milovanović, Zorka M.
AU  - Opric, M
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2836
AB  - Sequence alterations in the RET proto-oncogene are becoming increasingly important to clinical assessment of the malignant disease of the thyroid. A spectrum of mutations is necessary to establish comprehensive phenotype to genotype relationship relevant to diagnosis and therapy of thyroid malignancies. We aimed to append to the increasing database of these oncogenic lesions and, therefore, analyzed DNA from tumor tissue and constitutive DNA from a patient with thyroid carcinoma. Mutational screening and sequence characterization of the RET proto-oncogene was performed to include part of the intronic sequences. We report a germline sequence variant in DNA from the patient diagnosed with microfollicular thyroid carcinoma. The carcinoma presented not as fully developed medullar carcinoma (MTC) but as microfollicular carcinoma with tendency to evolve into MTC. We characterized the sequence variant located in the intron 10 of the RET oncogene as an A to G substitution denoted IVS10 + 4G. The described sequence alteration generates a chi-like sequence surrounded by several chi-like sequences with recombinational potential. Such alteration may be involved in the pathogenesis of the microfollicular carcinoma via genome destabilization through homologous recombination in the process of tumor progression. This result further substantiates the importance of the database correlating specific sequence variations in the RET gene with distinct disease phenotypes.
T2  - Medical Oncology
T1  - Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence
VL  - 21
IS  - 4
SP  - 319
EP  - 323
DO  - 10.1385/MO:21:4:319
ER  - 

@article{
author = "Veljkovic, E and Dzodic, R and Neskovic, G and Stanojević, Boban and Milovanović, Zorka M. and Opric, M and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Sequence alterations in the RET proto-oncogene are becoming increasingly important to clinical assessment of the malignant disease of the thyroid. A spectrum of mutations is necessary to establish comprehensive phenotype to genotype relationship relevant to diagnosis and therapy of thyroid malignancies. We aimed to append to the increasing database of these oncogenic lesions and, therefore, analyzed DNA from tumor tissue and constitutive DNA from a patient with thyroid carcinoma. Mutational screening and sequence characterization of the RET proto-oncogene was performed to include part of the intronic sequences. We report a germline sequence variant in DNA from the patient diagnosed with microfollicular thyroid carcinoma. The carcinoma presented not as fully developed medullar carcinoma (MTC) but as microfollicular carcinoma with tendency to evolve into MTC. We characterized the sequence variant located in the intron 10 of the RET oncogene as an A to G substitution denoted IVS10 + 4G. The described sequence alteration generates a chi-like sequence surrounded by several chi-like sequences with recombinational potential. Such alteration may be involved in the pathogenesis of the microfollicular carcinoma via genome destabilization through homologous recombination in the process of tumor progression. This result further substantiates the importance of the database correlating specific sequence variations in the RET gene with distinct disease phenotypes.",
journal = "Medical Oncology",
title = "Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence",
volume = "21",
number = "4",
pages = "319-323",
doi = "10.1385/MO:21:4:319"
}

Veljkovic, E., Dzodic, R., Neskovic, G., Stanojević, B., Milovanović, Z. M., Opric, M.,& Dimitrijević, B. B.. (2004). Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence. in Medical Oncology, 21(4), 319-323.
https://doi.org/10.1385/MO:21:4:319

Veljkovic E, Dzodic R, Neskovic G, Stanojević B, Milovanović ZM, Opric M, Dimitrijević BB. Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence. in Medical Oncology. 2004;21(4):319-323.
doi:10.1385/MO:21:4:319 .

Veljkovic, E, Dzodic, R, Neskovic, G, Stanojević, Boban, Milovanović, Zorka M., Opric, M, Dimitrijević, Bogomir B., "Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence" in Medical Oncology, 21, no. 4 (2004):319-323,
https://doi.org/10.1385/MO:21:4:319 . .

TY  - CONF
AU  - Neskovic, GG
AU  - Veljkovic, E
AU  - Dzodic, R
AU  - Dimitrijević, Bogomir B.
PY  - 2002
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/6386
C3  - European Journal of Human Genetics
T1  - RET oncogene mutations in Serbian patients with thyroid medullary carcinoma
VL  - 10
SP  - 107
EP  - 107
UR  - https://hdl.handle.net/21.15107/rcub_vinar_6386
ER  - 

@conference{
author = "Neskovic, GG and Veljkovic, E and Dzodic, R and Dimitrijević, Bogomir B.",
year = "2002",
journal = "European Journal of Human Genetics",
title = "RET oncogene mutations in Serbian patients with thyroid medullary carcinoma",
volume = "10",
pages = "107-107",
url = "https://hdl.handle.net/21.15107/rcub_vinar_6386"
}

Neskovic, G., Veljkovic, E., Dzodic, R.,& Dimitrijević, B. B.. (2002). RET oncogene mutations in Serbian patients with thyroid medullary carcinoma. in European Journal of Human Genetics, 10, 107-107.
https://hdl.handle.net/21.15107/rcub_vinar_6386

Neskovic G, Veljkovic E, Dzodic R, Dimitrijević BB. RET oncogene mutations in Serbian patients with thyroid medullary carcinoma. in European Journal of Human Genetics. 2002;10:107-107.
https://hdl.handle.net/21.15107/rcub_vinar_6386 .

Neskovic, GG, Veljkovic, E, Dzodic, R, Dimitrijević, Bogomir B., "RET oncogene mutations in Serbian patients with thyroid medullary carcinoma" in European Journal of Human Genetics, 10 (2002):107-107,
https://hdl.handle.net/21.15107/rcub_vinar_6386 .